ADD-ON PEGINTERFERON ALFA-2A SIGNIFICANTLY REDUCES HBsAg LEVELS IN HBeAg-NEGATIVE, GENOTYPE D CHRONIC HEPATITIS B PATIENTS FULLY SUPPRESSED ON NUCLEOT(S)IDE ANALOGUE TREATMENT: THE HERMES STUDY

被引：6
|
作者：
Lampertico, P. [1 ]
Brunetto, M. R. [2 ]
Craxi, A. [3 ]
Gaeta, G. B. [4 ]
Rizzetto, M. [5 ]
Palmieri, G. [6 ]
Colombo, M. [1 ]
机构：
[1] Univ Milan, Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy
[2] Univ Hosp Pisa, Liver Unit, Reference Ctr Chron Liver Dis & HCC Tuscany Reg, Pisa, Italy
[3] Univ Palermo, DiBiMIS, Gastroenterol & Hepatol, Palermo, Italy
[4] Univ Naples 2, Sect Infect Dis & Viral Hepatitis, Dept Internal Med, Naples, Italy
[5] Univ Turin, Dept Gastroenterol, Turin, Italy
[6] Roche, Monza, Italy
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)30179-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LP25
引用
收藏
页码：S276 / S276
页数：1
相关论文
共 50 条
  • [21] HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT
    Goulis, I.
    Akriviadis, E.
    Karatapanis, S.
    Deutsch, M.
    Dalekos, G.
    Raptopoulou-Gigi, M.
    Drakoulis, C.
    Bakalos, G.
    Papatheodoridis, G.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S286 - S287
  • [22] KINETICS OF HBSAG DECLINE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A ACCORDING TO GENOTYPE AND ITS ASSOCIATION WITH SUSTAINED HBSAG CLEARANCE 4 YEARS POST-TREATMENT
    Brunetto, Mourizia
    Bonino, Ferruccio
    Marcellin, Patrick
    Button, Peter
    Batrla, Richard
    HEPATOLOGY, 2008, 48 (04) : 740A - 740A
  • [23] RESPONSE TO PEGINTERFERON ALFA-2A IN HBEAG-NEGATIVE CHB: BASELINE AND ON-TREATMENT KINETICS OF HBSAG SERUM LEVELS VARY ACCORDING TO HBV GENOTYPE
    Brunetto, Maurizia R.
    Marcellin, Patrick
    Cherubini, Beatrice
    Yurdaydin, Cihan
    Farci, Patrizia
    Hadziyannis, Stephanos J.
    Rothe, Vivien
    Regep, Loredana
    Kapprell, Hans-Peter
    Bonino, Ferruccio
    HEPATOLOGY, 2011, 54 : 1059A - 1059A
  • [24] ON-TREATMENT MONITORING OF HBsAg LEVELS TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B
    Lau, G. K. K.
    Marcellin, P.
    Brunetto, M.
    Piratvisuth, T.
    Kapprell, H. -P
    Messinger, D.
    Popescu, M.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S333 - S333
  • [25] EARLY PREDICTION OF SUSTAINED RESPONSE TO PEGINTERFERON ALFA-2A IN HBEAG-NEGATIVE PATIENTS: THE ROLE OF ON-TREATMENT HBSAG AND HBV DNA LEVELS
    Rijckborst, V.
    Hansenu, B. E.
    Cakaloglu, Y.
    Ferenci, P.
    Tabak, F.
    Akdogan, M.
    Simon, K.
    Akarca, U. S.
    Flisiak, R.
    Verhey, E.
    van Vuuren, A. J.
    Boucher, C. A. B.
    ter Borg, M. J.
    Janssen, H. L. A.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S4 - S5
  • [26] A GENOTYPE-SPECIFIC BASELINE SCORE TO PREDICT RESPONSE AT 48 WEEKS POST-TREATMENT TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B
    Lampertico, P.
    Messinger, D.
    Cornberg, M.
    Brunetto, M.
    Petersen, J.
    Kennedy, P.
    Asselah, T.
    Rothe, V.
    Caputo, A.
    Bakalos, G.
    Pavlovic, V.
    Papatheodoridis, G. V.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S599 - S600
  • [27] Response to peginterferon alfa-2a (40KD) (PEGASYS) treatment in patients with bridging fibrosis in HBeAg-positive and HBeAg-negative chronic hepatitis B
    Cooksley, Graham
    Lau, George
    Marcellin, Patrick
    Piratvisuth, Teerha
    Lai, Ming-Yang
    Bonino, Ferruccio
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A32 - A32
  • [28] INTRAHEPATIC HBSAG PREDICTS TREATMENT RESPONSE IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A AND ADEFOVIR: AN INTERIM ANALYSIS
    Takkenberg, Bart
    Terpstra, Valeska
    Zaaijer, Hans L.
    Weegink, Christine J.
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Beld, Marcel
    Reesink, Hendrik W.
    HEPATOLOGY, 2010, 52 (04) : 988A - 988A
  • [29] Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels
    Hall, Samuel A. L.
    Burns, Gareth S.
    Anagnostou, Despina
    Vogrin, Sara
    Sundararajan, Vijaya
    Ratnam, Dilip
    Levy, Miriam T.
    Lubel, John S.
    Nicoll, Amanda J.
    Strasser, Simone, I
    Sievert, William
    Desmond, Paul, V
    Ngu, Meng C.
    Angus, Peter
    Sinclair, Marie
    Meredith, Christopher
    Matthews, Gail
    Revill, Peter A.
    Jackson, Kathy
    Littlejohn, Margaret
    Bowden, D. Scott
    Locarnini, Stephen A.
    Visvanathan, Kumar
    Thompson, Alexander J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (02) : 310 - 320
  • [30] Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype
    Brunetto, Maurizia R.
    Marcellin, Patrick
    Cherubini, Beatrice
    Yurdaydin, Cihan
    Farci, Patrizia
    Hadziyannis, Stephanos J.
    Rothe, Vivien
    Regep, Loredana
    Bonino, Ferruccio
    JOURNAL OF HEPATOLOGY, 2013, 59 (06) : 1153 - 1159
12345